How has the COVID-19 pandemic affected our rheumatology patients using biological/targeted DMARDs?

Semih Gulle,Yesim Erez,Ali Karakas,Tuba Yuce Inel,Sinem Burcu Kocaer,Tuba Demirci Yildirim,Gercek Can,Ismail Sari,Merih Birlik,Fatos Onen

ANNALS OF THE RHEUMATIC DISEASES（2023）

引用 0|浏览4

暂无评分

摘要

It was shown that approximately 1/5 of iRMD patients using b/tsDMARDs delayed their treatment due to the fear of COVID-19 in the first three months of the pandemic process. However, with good communication with the patients, b/tsDMARD treatment was restarted and the 12-month drug retention status was quite high.

查看译文

关键词

biological/targeted dmards,rheumatology patients,pandemic

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要